Cell-based Assay Market Share, Size, Trends, Industry Analysis Report, By Product (Consumable, Assay kits, Cell lines); By Type (Drug Discovery, Basic Research, ADME Studies); By End-Use; By Region; Segment Forecast, 2022 - 2030
- Published Date:Sep-2022
- Pages: 118
- Format: PDF
- Report ID: PM2600
- Base Year: 2021
- Historical Data: 2018-2020
Report Outlook
The global Cell-based Assay market was valued at USD 15.91 billion in 2021 and is expected to grow at a CAGR of 8.2% during the forecast period. The growing demand for cell-based assay is expected to be driven by the increasing number of drug development activities and the adoption of cell-based assay techniques in the industries.
Know more about this report: Request for sample pages
They are growing in demand due to the increasing incidence of chronic diseases and technological advancements. Adopting throughput screening methodology is expected to drive market growth. Furthermore, in a regulated environment, these cell-based assays are used for cytotoxicity studies, determination of the mechanism of action, and immunogenicity studies, which are expected to impact the industry growth positively.
The COVID-19 pandemic positively impacted the growth of the cell-based assay market. The increased demand for Covid-19 research has created a range of cell-based trials in viral infection research, vaccine development, and holistic drug discovery. However, it is used to reduce the time and increase throughput efficiency and also provides an early indication of any toxic properties, which has dramatically increased the need for cell-based assay.
As the pharmaceutical industry needs to discover medicines efficiently and drive innovation, the industry is likely to adopt the approach of rapid assay-based techniques owing to its better level of accuracy and cost-effectiveness. In addition, the growing usage of cell-based assays on live cells during experiments to represent live cell models and becoming an essential tool for the development of various antibodies and understanding cell functions is likely to complement industry growth over the forecast period.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
The global cell-based assay industry is likely to be driven by the rising demand in Asia Pacific owing to the increasing government investment in R&D infrastructure and pharmaceutical & biotechnology companies and many CROs replacing many biochemical assay techniques in the process of drug discovery in India and Japan. Furthermore, the increasing cases of deadly virus resulted in many research activities, which is expected to fuel the growth of the industry.
Furthermore, the cell-based assays provide accurate responses regarding tissues, protein, and other materials as well. As a result, the demand for the cell-based assay is likely to drive the growth of the industry.
Report Segmentation
The market is primarily segmented based on product, type, end-use, and region.
|
By Product |
By Type |
By End-Use |
By Region |
|
|
|
|
Know more about this report: Request for sample pages
Consumable product segment accounted for the largest share in 2021
The consumable market segment accounted for the highest revenue share in 2021, owing to heavy usage of consumable products and usage by many biopharma and biotech companies for the development and production of cells, especially in an emerging market. In addition, the increasing demand for the development of research activities in therapeutics is expected to complement market growth over the forecast period.
Drug Discovery are expected to spearhead the market growth
The demand for drug discovery is driven by the rising demand from the biotechnological and pharmaceutical industries. The high growth is attributed to the massive investment in research activities by biopharmaceutical companies, which is expected to drive the need for the segment over the upcoming years.
In addition, the primary research segment is also expected to upscale during the forecast period owing to the application of cell-based assays in many chronic illnesses across developing countries. The research on many cardiovascular conditions also needs attention, propelling the market's growth.
Biopharmaceutical and pharmaceutical segment is expected to account for the largest share in 2030
Biopharmaceutical and pharmaceutical is expected to dominate the market over the forecast period owing to the increasing adoption of the cell-based assay in various biotech and pharma companies due to its advantages. The growing need to ensure that cell is properly proliferated and measure their toxicity and mobility is likely to positively impact the revenue growth over the forecast period.
Academic & government research institutes is expected to be another significant application for the cell-based assay market owing to the adoption of many strategic approaches to research various genes, proteins, and tissues. In addition, demand for assay-based techniques is at boom due to their accuracy, which significantly impacts the market growth.
Asia Pacific is expected to dominate and witness fastest growth over the forecast period
Asia Pacific is the largest region for the cell-based assay market. It is expected to witness faster growth over the forecast period owing to the initiatives taken by the many biopharma companies undergoing collaborations to develop new drugs and many initiatives taken by governments for infrastructural development across the countries. In addition, the growing demand for the development of drugs across developing countries is expected to drive demand over the forecast period.
North America dominates the cell-based assay market because of the growing number of patients dealing with severe chronic diseases such as diabetes, arthritis, and cancer. Furthermore, the penetration of CROs and the adoption of various advanced technologies will likely positively impact revenue growth.
Competitive Insight
Some of the major players operating in the global market include Biognosys, Charles River Laboratories, Inc., Cell Signaling Technologies, Cisbio, Cell Biolabs, Inc., Dickinson and Company, Danaher Corporation, GE Healthcare, Lonza Group, Beckman Coulter,Inc., Bio-Rad Laboratories, Inc.,General Electric, Merck KGaA, Novartis AG, PerkinElmer, Inc., Promega Corporation and Thermo Fisher Scientific, Inc.
Recent Developments
In June 2021, Danaher Corporation announced the acquisition of Aldevron company which manufactures mRNA, Proteins and has reach many biotechnology and pharmaceutical consumers. This acquisition will lead the field of development of genomic medicine.
In March 2020, Promega corporation announced a strategic partnership with FUJIFILM Cellular Dynamics, which will develop drug discovery to an advanced novel assay to observe how cells behave in the human body.
Cell-based Assay Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2021 |
USD 15.91 billion |
|
Revenue forecast in 2030 |
USD 32.23 billion |
|
CAGR |
8.2% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Product, By Type, By End-Use, and By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Charles River Laboratories, Inc., Cell Signaling Technologies, Cisbio, Cell Biolabs, Inc., Dickinson and Company, Danaher Corporation, GE Healthcare, Lonza Group, Beckman Coulter,Inc., Bio-Rad Laboratories, Inc.,General Electric, Merck KGaA, Novartis AG, PerkinElmer, Inc., Promega Corporation and Thermo Fisher Scientific, Inc. |
